MedPharm has spent more than two decades developing complex topical and transepithelial drug products. That depth of experience spans local delivery to the skin as well as delivery across other epithelial barriers, including the nail, eye, nasal and pulmonary routes, mucosal tissues such as vaginal, and other specialised or unconventional routes of delivery such as joints, bladder, and gastrointestinal. This gives sponsors a single partner across a wide range of administration routes.
Supporting this breadth of routes is an extensive toolbox of preclinical models that MedPharm integrates directly into the formulation development process. These models are used to screen and de-risk candidate formulations at every stage, from early prototype formulations through late-stage formulations that meet the quality standards required for regulatory submission. Unlike models built on animal tissue or artificial membranes, MedPharm's toolbox relies primarily on human-derived living constructs, avoiding the gaps in clinical translation that come from species differences and artificial systems. These living models capture the unique barrier properties of each route of delivery, from the ciliary clearance and mucus layer of the nasal passage to the protective barrier of the skin. This allows MedPharm to assess local pharmacokinetics, local pharmacodynamics, target engagement, and underlying biology under physiologically relevant conditions that reflect the tissue a formulation will encounter.
These barrier differences mean no single formulation strategy works across every route of delivery. MedPharm builds each formulation around the specific drug it is designed to deliver, while keeping the barrier it must cross in mind from the earliest stages of development. As a lead formulation takes shape, MedPharm's formulators begin thinking ahead to scale-up and process development, rather than the programme later being handed off to a different team or manufacturing site. This continuity de-risks product failure and streamlines the transition into manufacturing. It also shortens development timelines and minimises the unknowns that often surface when a programme changes hands, which is what makes MedPharm a true end-to-end CDMO, carrying a programme from early-stage development through commercial manufacturing.
Few providers in the topical and transepithelial space offer this same breadth in a single partner, spanning formulation development across multiple routes of delivery, device and combination products, IVRT and IVPT, clinical trial material manufacturing, and commercial GMP production. Through its multiple sites and its partnership with Purna Pharmaceuticals, MedPharm offers manufacturing in the United States, the United Kingdom, and Belgium, giving sponsors flexibility in where a product is manufactured as trade and tariff considerations increasingly shape sourcing decisions. This footprint allows MedPharm to support sponsors on a global scale from concept through commercial supply.
Whether advancing a novel therapy or improving an established product, MedPharm brings more than two decades of scientific depth, a proprietary preclinical toolbox spanning early feasibility through post-approval claim support, and an integrated development and manufacturing model to help bring innovative medicines to patients.
